1. NOVEL CLL TREATMENTS

Dr Mary-Ann Anderson examines the non-chemoimmunotherapy treatment options available for clinicians, and the many different factors that go into choosing between them for an individual patient.

2. SEQUENCING VENCLEXTA IN CLL: CLINICAL TRIAL EVIDENCE

Dr Mary-Ann Anderson discusses the time off treatment data from the CLL14 and MURANO trials, and the data available for patients who received subsequent treatment after the MURANO trial.

3. SEQUENCING VENCLEXTA IN CLL: REAL-WORLD EVIDENCE

Dr Mary-Ann Anderson examines the real-world evidence available for sequencing different CLL therapies, and the limitations of that evidence.